CNMD has strung together four consecutive earnings beats averaging approximately 5.5% positive surprise, and free cash flow runs at 229% of net income — strong operational quality signals — but a confirmed price downtrend with the 200-day moving average slope declining at -5.5% over 30 days, a put/call ratio of 6.00, and less than 1% headroom to the analyst target make this a high-quality business in an unfavorable technical and positioning setup.
Thesis pillars
- Unbroken Four Quarter Beat Streak→Stable
- Exceptional Cash Conversion Quality→Stable
- Confirmed Downtrend Blocks Entry→Stable
- +1 more pillar — see the Why tab for full reasoning
CONMED Corporation (CNMD) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $33.83 — A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative news sentiment (-0.67).
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture... Read more
Sell if holding. Analyst target reached at $33.83 — A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative news sentiment (-0.67). Chart setup: Death cross but MACD improving, RSI 48. Score 5.2/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — CONMED Corporation
Latest news
- NEWS CONMED ($CNMD) Releases Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative neutral
- NEWS Conmed (CNMD) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS CONMED’s (NYSE:CNMD) Q1 CY2026 Sales Beat Estimates - StockStory — StockStory positive
- NEWS Earnings Flash (CNMD) CONMED Corporation Posts Q1 Adjusted EPS $0.89 per Share, vs. FactSet Est of $0.82 - marketscreene — marketscreener.com positive
- NEWS CONMED (CNMD) Stock: Price Action Analysis | Q4 2025: EPS Beats Forecasts - Most Watched Stocks - Cổng thông tin điện tử — Cổng thông tin điện tử Tỉnh Sơn La positive
Generated 2026-07-05T12:40:25Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $33.83 — A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Negative news sentiment (-0.67). Chart setup: Death cross but MACD improving, RSI 48. Prior stop was $31.46. Score 5.2/10, moderate confidence.
Take-profit target: $34.45 (+1.8% upside). Prior stop was $31.46. Stop-loss: $31.46.
Analyst target reached - limited upside remaining; Negative news sentiment (-0.67); Negative momentum.
CONMED Corporation trades at a P/E of 19.1 (forward 7.1). TrendMatrix value score: 8.0/10. Verdict: Sell.
11 analysts cover CNMD with a consensus score of 2.5/5. Average price target: $40.
What does CONMED Corporation do?CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical...
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.